Eisai To Begin China Final-Phase Trials Of Halaven This Summer
This article was originally published in PharmAsia News
Executive Summary
Eisai said it plans to begin Phase III trials in China this summer of Halaven (eribulin) for breast cancer, a drug the Japan firm is banking on to be a large revenue producer to replace blockbusters that lost patent protection.